FinTrust Capital Advisors LLC increased its holdings in shares of Luminex Co. (NASDAQ:LMNX) by 307.6% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 25,222 shares of the medical instruments supplier’s stock after acquiring an additional 19,034 shares during the quarter. FinTrust Capital Advisors LLC owned about 0.05% of Luminex worth $820,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also bought and sold shares of the company. CFM Wealth Partners LLC acquired a new position in Luminex in the 2nd quarter valued at about $32,000. Macquarie Group Ltd. acquired a new position in Luminex in the 2nd quarter valued at about $45,000. Mutual of America Capital Management LLC boosted its holdings in Luminex by 22.9% in the 1st quarter. Mutual of America Capital Management LLC now owns 1,844 shares of the medical instruments supplier’s stock valued at $51,000 after purchasing an additional 344 shares during the last quarter. Meeder Asset Management Inc. boosted its holdings in Luminex by 6,283.8% in the 1st quarter. Meeder Asset Management Inc. now owns 2,362 shares of the medical instruments supplier’s stock valued at $64,000 after purchasing an additional 2,325 shares during the last quarter. Finally, Banque Cantonale Vaudoise acquired a new position in Luminex in the 1st quarter valued at about $70,000. Hedge funds and other institutional investors own 93.69% of the company’s stock.
In other news, CEO Nachum Shamir sold 125,000 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $38.51, for a total value of $4,813,750.00. Following the completion of the transaction, the chief executive officer now owns 314,024 shares in the company, valued at approximately $12,093,064.24. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, SVP Richard W. Rew II sold 7,389 shares of the company’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $38.93, for a total transaction of $287,653.77. Following the completion of the transaction, the senior vice president now owns 40,542 shares of the company’s stock, valued at approximately $1,578,300.06. The disclosure for this sale can be found here. Over the last three months, insiders sold 649,397 shares of company stock worth $24,519,194. Insiders own 9.40% of the company’s stock.
Luminex (NASDAQ:LMNX) last issued its quarterly earnings data on Tuesday, August 4th. The medical instruments supplier reported $0.27 EPS for the quarter, topping the consensus estimate of $0.08 by $0.19. Luminex had a net margin of 3.04% and a return on equity of 2.38%. The firm had revenue of $109.52 million for the quarter, compared to analyst estimates of $107.33 million. During the same period in the prior year, the business posted ($0.11) EPS. The business’s revenue for the quarter was up 31.9% compared to the same quarter last year. Equities analysts forecast that Luminex Co. will post 0.81 earnings per share for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Thursday, October 15th. Shareholders of record on Thursday, September 24th will be given a $0.09 dividend. This represents a $0.36 dividend on an annualized basis and a dividend yield of 1.46%. The ex-dividend date is Wednesday, September 23rd. Luminex’s dividend payout ratio is presently -171.43%.
Several equities analysts have weighed in on the stock. TheStreet upgraded shares of Luminex from a “c” rating to a “b” rating in a report on Wednesday, August 5th. BidaskClub lowered shares of Luminex from a “hold” rating to a “sell” rating in a report on Saturday, August 29th. Zacks Investment Research lowered shares of Luminex from a “buy” rating to a “hold” rating and set a $26.00 price objective on the stock. in a report on Friday, September 4th. Finally, Piper Sandler began coverage on shares of Luminex in a report on Tuesday, August 18th. They issued a “buy” rating and a $38.00 price objective on the stock. Two analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average price target of $29.25.
Luminex Corporation develops, manufactures, and sells proprietary biological testing technologies and products for the diagnostics, pharmaceutical, and research industries worldwide. Its products include Luminex 100/200 that integrates fluidics, optics, and digital signal processing; FLEXMAP 3D system for use as a general laboratory instrument; MAGPIX system, a multiplexing analyzer for qualitative and quantitative analysis of proteins and nucleic acids; ARIES system, a sample to answer real-time PCR platform; ARIES M1 system, a single-module version of the ARIES System; and VERIGENE system, a semi-automated, multiplex, molecular analysis system for the clinical diagnostics market.
Further Reading: What does a dividend yield signify to investors?
Receive News & Ratings for Luminex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Luminex and related companies with MarketBeat.com's FREE daily email newsletter.